{"id":56057,"date":"2026-02-02T21:12:30","date_gmt":"2026-02-02T13:12:30","guid":{"rendered":"https:\/\/flcube.com\/?p=56057"},"modified":"2026-02-02T21:12:33","modified_gmt":"2026-02-02T13:12:33","slug":"abb-bio-techs-trivalent-influenza-vaccine-wins-nmpa-nod-for-all-ages","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56057","title":{"rendered":"Ab&b Bio-Tech’s Trivalent Influenza Vaccine Wins NMPA Nod for All Ages"},"content":{"rendered":"\n

Ab&b Bio-Tech Co.,Ltd.<\/strong> (HKG: 2627<\/a>) announced that the National Medical Products Administration (NMPA)<\/strong> has granted marketing approval for its trivalent influenza virus subunit vaccine<\/strong> for all age groups<\/strong>, making it the first and only<\/strong> trivalent influenza subunit vaccine approved in China across the full age spectrum at full dosage.<\/p>\n\n\n\n

Regulatory Milestone & Product Profile<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Ab&b Bio-Tech Co.,Ltd.<\/td><\/tr>
Product<\/strong><\/td>Trivalent influenza virus subunit vaccine<\/td><\/tr>
Approval<\/strong><\/td>NMPA marketing authorization<\/td><\/tr>
Indication<\/strong><\/td>All age groups<\/td><\/tr>
Innovation<\/strong><\/td>Upgrade from traditional split\u2011virus vaccines<\/td><\/tr>
Key Advantages<\/strong><\/td>Comprehensive protection, high antigen purity, lower adverse reaction risk<\/td><\/tr>
Market Position<\/strong><\/td>First and only trivalent influenza subunit vaccine for all ages in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Commercial Outlook<\/h2>\n\n\n\n